Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type 1 Diabetes AND Diabetes AND Exenatide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    52 result(s) found for: Type 1 Diabetes AND Diabetes AND Exenatide. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-006092-21 Sponsor Protocol Number: NN2211-1797 Start Date*: 2007-05-14
    Sponsor Name:Novo Nordisk a/s
    Full Title: Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes A 26-week randomised, open-label, active compara...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) FI (Completed) DE (Completed) ES (Completed) DK (Completed) SI (Completed) FR (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003738-25 Sponsor Protocol Number: ESR-16-12160/UKE-DapEx-001 Start Date*: 2017-12-28
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared...
    Medical condition: Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005220-16 Sponsor Protocol Number: SöS exendin 1 Start Date*: 2007-06-11
    Sponsor Name:Karolinska institutet
    Full Title: Cardiovascular fysiological effects of Exenatide on heart failure
    Medical condition: We are studying a diabetic ( type II) population with decompensated heart failure. Our aim is to see wether Cardiac index and "wedge pressure", measured by heart catheterization, can improve with ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    9.1 10066159 Decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005883-28 Sponsor Protocol Number: EFC6019 Start Date*: 2008-05-19
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, open-label, active-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 versus exenatide on top of metform...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    10.1 10067585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) ES (Completed) DK (Completed) HU (Completed) NL (Completed) GR (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002957-22 Sponsor Protocol Number: H80-MC-GWBR Start Date*: 2008-03-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea.
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) BE (Completed) DK (Completed) GR (Completed) FR (Completed) CZ (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004826-92 Sponsor Protocol Number: NN9535-3624 Start Date*: 2013-09-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) NL (Completed) FI (Completed) GR (Completed) GB (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012011-17 Sponsor Protocol Number: H8O-MC-GWDE Start Date*: 2009-11-19
    Sponsor Name:Eli Lilly and Company
    Full Title: Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in subjects with type 2 diabetes and inadequate glycemic control treated with lifestyle modification and oral antidiabetic medications
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) SK (Completed) IT (Completed) AT (Completed) GR (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-000854-11 Sponsor Protocol Number: H80-MC-GWCH Start Date*: 2008-09-26
    Sponsor Name:Eli Lilly and Company
    Full Title: Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) SK (Completed) ES (Completed) FR (Completed) DE (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001365-92 Sponsor Protocol Number: 1 Start Date*: 2016-10-10
    Sponsor Name:Center for Diabetes Research, Gentofte Hospital
    Full Title: Meal-time Administration of exenatide for Glycaemic control in type 1 diabetic Cases: A randomised, placebo-controlled trial
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021069-63 Sponsor Protocol Number: BCB109(H8O-MC-GWDQ) Start Date*: 2011-06-23
    Sponsor Name:Amylin Pharmaceuticals, LLC
    Full Title: A randomized, placebo, controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide Once Weekly in patients with type 2 diabetes mellitus
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) LV (Completed) AT (Completed) GB (Completed) CZ (Completed) SK (Completed) HU (Completed) BG (Completed) IT (Completed) BE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005196-16 Sponsor Protocol Number: H8O-MC-GWBQ Start Date*: 2012-07-24
    Sponsor Name:Amylin Pharmaceuticals, Inc.
    Full Title: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes
    Medical condition: Treatment of Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016384-11 Sponsor Protocol Number: 09-112 Start Date*: 2010-05-17
    Sponsor Name:CHU Caen
    Full Title: Effects of EXEnatide on Glycemic Control and Weight over 26 weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients with Type 2 Diabetes : a phase 2/3 doUble blind randoMized Plac...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    Population Age: Gender:
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001938-41 Sponsor Protocol Number: H8O-SB-GWBN(a) Start Date*: 2007-02-07
    Sponsor Name:Lilly Deutschland GmbH
    Full Title: Effect of Exenatide plus Metformin vs. Premixed Human Insulin Aspart plus Metformin on Glycemic Control and Hypoglycemia in Patients with Inadequate Control of Type 2 Diabetes on Oral Antidiabetic ...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003843-36 Sponsor Protocol Number: H8O-US-GWCO Start Date*: 2008-09-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Trial Comparing Exenatide with Placebo in Subjects with Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005242-60 Sponsor Protocol Number: UoL001187 Start Date*: 2016-10-03
    Sponsor Name:University of Liverpool
    Full Title: RESILIENT: RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) pati...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004850-32 Sponsor Protocol Number: EFC13794 Start Date*: 2016-06-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabe...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006149-15 Sponsor Protocol Number: H80-MC-GWBO Start Date*: 2007-06-21
    Sponsor Name:Eli Lilly and Company
    Full Title: The effect of treatment interruption on safety and efficacy of exenatide in patients with Type 2 Diabetes.
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005325-10 Sponsor Protocol Number: DC2008exe001 Start Date*: 2009-04-08
    Sponsor Name:VU University Medical Center
    Full Title: The effect of exenatide compared to insulin glargine on cardiac function and metabolism in type 2 diabetic patients with congestive heart failure (NYHA II): a randomized-controlled trial
    Medical condition: Cardiac function and metabolism in type 2 diabetic patients with congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    9.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001454-33 Sponsor Protocol Number: DEXBASU Start Date*: 2017-08-07
    Sponsor Name:Dr. Albert Lecube Torello
    Full Title: A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surg...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002219-25 Sponsor Protocol Number: ITCA650-CLP-107 Start Date*: 2014-09-16
    Sponsor Name:Intarcia Therapeutics, Inc.
    Full Title: A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) EE (Completed) FI (Completed) DE (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 05:07:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA